151427-19-9

Basic information

• Product Name: 2-BROMO-1-(2,3-DIHYDRO-1-BENZOFURAN-5-YL)ETHANONE
• Synonyms: 2-broMo-1-(2,3-dihydrobenzofuran-5-yl)ethanone;2-bromo-1-(2,3-dihydro-1-benzofuran-5-yl)ethan-1-one
• CAS NO: 151427-19-9
• Molecular Formula: C₁₀H₉BrO₂
• Molecular Weight: 241.09
• Mol File: 151427-19-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 356.4°Cat760mmHg
• Flash Point: 169.3°C
• Appearance: /
• Density: 1.562g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.606
• CAS DataBase Reference: 2-BROMO-1-(2,3-DIHYDRO-1-BENZOFURAN-5-YL)ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-1-(2,3-DIHYDRO-1-BENZOFURAN-5-YL)ETHANONE(151427-19-9)
• EPA Substance Registry System: 2-BROMO-1-(2,3-DIHYDRO-1-BENZOFURAN-5-YL)ETHANONE(151427-19-9)

Safety Data

• Hazardous Substances Data: 151427-19-9(Hazardous Substances Data)

Usage

General Description

2-BROMO-1-(2,3-DIHYDRO-1-BENZOFURAN-5-YL)ETHANONE is a chemical compound with the molecular formula C10H9BrO2. It is a brominated ketone derivative containing a benzofuran ring. This chemical is commonly used in organic synthesis and medicinal chemistry as a building block for the preparation of various pharmaceuticals and natural products. It has also been studied for its potential biological activities, such as antifungal and antibacterial properties. Additionally, it is a useful reagent in the preparation of other biologically active compounds and aromatic ethers. Overall, 2-BROMO-1-(2,3-DIHYDRO-1-BENZOFURAN-5-YL)ETHANONE plays an important role in the development of new drugs and agrochemicals.

InChI:InChI=1/C10H9BrO2/c11-6-9(12)7-1-2-10-8(5-7)3-4-13-10/h1-2,5H,3-4,6H2

Upstream product

• 496-16-2 2.3-dihydrobenzofuran 
• 22118-09-8 2-bromoacetyl chloride 
• 90843-31-5 1-(2,3-dihydrobenzofuran-5-yl)ethanone 

Downstream Products

• 133099-07-7 (S)-darifenacin hydrobromide 
• 127264-14-6 2,3-dihydro-5-(2-bromoethyl)benzofuran 
• 133099-04-4 darifenacin 
• 262847-54-1 2,3-dihydrobenzofuran-5-carboxamide 

Relevant articles and documents

ANTIBACTERIAL COMPOUNDS

The present invention relates to compounds of general formula (II),to compositions comprising these compounds and to methods of treating Enterobacteriaceae bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Enterobacteriaceae.

Design, synthesis and structure-activity relationship studies of novel and diverse cyclooxygenase-2 inhibitors as anti-inflammatory drugs

Because of the pivotal role of cyclooxygenase (COX) in the inflammatory processes, non-steroidal anti-inflammatory drugs (NSAIDs) that suppress COX activities have been used clinically for the treatment of inflammatory diseases/syndromes; however, traditional NSAIDs exhibit serious side-effects such as gastrointestinal damage and hyper sensitivity owing to their COX-1 inhibition. Also, COX-2 inhibition-derived suppressive or preventive effects against initiation/proliferation/invasion/motility/recurrence/metastasis of various cancers/tumours such as colon, gastric, skin, lung, liver, pancreas, breast, prostate, cervical and ovarian cancers are significant. In this study, design, synthesis and structure-activity relationship (SAR) of various novel {2-[(2-, 3- and/or 4-substituted)-benzoyl, (bicyclic heterocycloalkanophenyl)carbonyl or cycloalkanecarbonyl]-(5- or 6-substituted)-1H-indol-3-yl}acetic acid analogues were investigated to seek and identify various chemotypes of potent and selective COX-2 inhibitors for the treatment of inflammatory diseases, resulting in the discovery of orally potent agents in the peripheral-inflammation model rats. The SARs and physicochemical properties for the analogues are described as significant findings. For graphical abstract: see Supplementary Material. (www.informahealthcare.com/enz)

DIAMINOTHIAZOLES

The present invention is directed to novel diaminothiazoles of formula These compounds inhibit cyclin-dependent kinase 4 (Cdk4) and are selective against Cdk2 and Cdk1. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment 6r control of breast, lung and colon and prostate tumors.